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Abstract 52 
Malaria is a global health concern and research efforts are ongoing to develop a superior vaccine 53 
to RTS,S/AS01. To guide immunogen design, we seek a comprehensive understanding of the 54 
protective humoral response against Plasmodium falciparum circumsporozoite protein (PfCSP). 55 
In contrast to the well-studied responses to the repeat region and the C-terminus, the antibody 56 
response against the N-terminal domain of PfCSP (N-CSP) remains obscure. Here, we 57 
characterized the molecular recognition and functional efficacy of the N-CSP-specific monoclonal 58 
antibody 5D5. The crystal structure at 1.85 Å resolution revealed that 5D5 binds an a-helical 59 
epitope in N-CSP with high affinity through extensive shape and charge complementarity, and the 60 
unusual utilization of an N-linked glycan. Nevertheless, functional studies indicated low 5D5 61 
binding to live Pf sporozoites, and lack of sporozoite inhibition in vitro and in mosquitoes. Overall, 62 
our data on low recognition and inhibition of sporozoites do not support the inclusion of the 5D5 63 
epitope into the next generation of CSP-based vaccines.  64 
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Summary Statement 65 
The Plasmodium falciparum sporozoite surface protein, PfCSP, is an attractive vaccine target, but 66 
the antibody response against the CSP N-terminal domain has remained understudied. Here, to 67 
guide immunogen design, Thai et al. provide insights into the binding motif and functional efficacy 68 
of the N-terminal domain-specific monoclonal antibody, 5D5.  69 
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Introduction 70 
Malaria is a vector-borne disease of global importance. In 2017, an estimated 219 million 71 
cases were reported, resulting in 435,000 deaths (WHO, 2018). The majority of deaths are caused 72 
by Plasmodium falciparum (Pf), making this parasite a central focus of research efforts for the 73 
development of effective therapeutic interventions. Anti-infection vaccines target the sporozoite 74 
stage of the Pf life cycle as parasites are transmitted to the human host by infected female 75 
Anopheles mosquitos during a blood meal. It has been established four decades ago that mAbs 76 
targeting the sporozoite surface circumsporozoite protein (CSP) are capable of neutralizing 77 
Plasmodium infection (Potocnjak et al., 1980; Yoshida et al., 1980; Yoshida et al., 1981; Cochrane 78 
et al., 1982). This year, the current leading anti-infection CSP-based vaccine against Pf malaria, 79 
RTS,S/AS01, has begun pilot implementation in Ghana, Malawi and Kenya. Notwithstanding, 80 
RTS,S/AS01 has shown to only provide rapidly waning protection in 50% of children and thus, 81 
intense research efforts are underway towards designing a more efficacious and durable anti-CSP 82 
vaccine (RTS,S Clinical Trials Partnership, 2015; Julien and Wardemann, 2019). 83 
A molecular understanding of how the most potent monoclonal antibodies (mAbs) 84 
recognize sites of vulnerability on the parasite can guide next-generation vaccine design. PfCSP is 85 
composed of an N-terminal domain (N-CSP), a central repeat region comprising NANP motifs of 86 
varied number that are interspersed with related NVDP motifs, and a C-terminal domain (C-CSP) 87 
that comprises a linker region preceding an α-thrombospondin type-1 repeat (αTSR) domain (Fig. 88 
1A). PfCSP is linked to the parasite membrane through a glycosylphosphatidylinositol anchor site. 89 
Numerous studies have shown that mAbs specific for the NANP repeat region and the junction 90 
immediately following N-CSP, which contains NANP motifs, NVDV motifs and the only copy of 91 
an NPDP motif, can mediate protection in animal models (Potocnjak et al., 1980; Yoshida et al., 92 
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1980; Foquet et al., 2014; Oyen et al., 2017; Triller et al., 2017; Kisalu et al., 2018; Tan et al., 93 
2018; Imkeller et al., 2018; Murugan et al., 2019). The few described mAbs to C-CSP were 94 
functionally ineffective, probably, due to low accessibility of this domain on the sporozoite surface 95 
(Scally et al., 2018). In contrast, the functional relevance of N-CSP mAbs remains elusive. To 96 
date, no human mAb specific for this domain and only a handful of murine mAbs from 97 
immunization studies with recombinant Pf N-CSP have been reported (Espinosa et al., 2015; 98 
Herrera et al., 2015). These mAbs recognized N-CSP epitopes adjacent to Region I (RI; Fig. 1A), 99 
a site with high conservation across Plasmodium species, suggesting that RI may be a good target 100 
for cross-species vaccine development (Dame et al, 1984; Espinosa et al., 2015). Additionally, 101 
proteolytic cleavage of RI was linked to efficient sporozoite invasion of host hepatocytes (Espinosa 102 
et al., 2015; Coppi et al., 2005). Based on these observations, it has been proposed that adding N-103 
CSP, including the RI motif, into a PfCSP subunit vaccine may improve protective efficacy 104 
compared to the current leading vaccine RTS,S/AS01, which lacks this domain. However, passive 105 
transfer of the most potent RI-targeting mAb 5D5 protected mice from infection in only one of the 106 
two tested transgenic rodent P. berghei (Pb) models that expressed a chimeric PbCSP with the Pf 107 
N-CSP domain (Espinosa et al., 2015), and its impact on Pf has not been determined. Thus, crucial 108 
information on how mAb 5D5 binds and inhibits Pf sporozoites is still missing. 109 
To gain a molecular understanding of how the mAb 5D5 recognizes PfCSP and inhibits Pf 110 
sporozoite infectivity, we solved the crystal structure of the 5D5 Fab in complex with a peptide 111 
derived from N-CSP and conducted in-depth binding and functional experiments with Pf 112 
sporozoites. We specifically quantified reactivity of mAb 5D5 to single live Pf sporozoites isolated 113 
from the midgut and salivary glands of mosquitoes using imaging flow cytometry, and tested its 114 
inhibitory potency against Pf sporozoites through in vitro traversal assays and in vivo passive mAb 115 
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transfer experiments in mosquitoes. Our work provides a detailed molecular and functional 116 
understanding of mAb 5D5 recognition of its epitope, and highlights poor recognition of this N-117 
CSP epitope on the Pf sporozoite surface. 118 
 119 
Results and Discussion 120 
mAb 5D5 binds an α-helical motif in N-CSP 121 
To understand the molecular basis for mAb 5D5 recognition of PfCSP, we solved the 122 
crystal structure of the 5D5 Fab in complex with PfCSP81-98 to 1.85 Å resolution (Supplementary 123 
Table 1). We specifically selected PfCSP residues 81-98 for our studies to ensure inclusion of the 124 
mAb 5D5 epitope, identified as Pf N-CSP residues 82-91 by yeast display epitope mapping (Fig.  125 
1A and S1A) in agreement with previous reports (Espinosa et al., 2015), as well as conserved RI 126 
residues KLKQP in positions 93-97. Consistent with our yeast display experiments, we observed 127 
strong electron density for N-CSP residues 81-92 (EDNEKLRKPKHK) in the crystal structure 128 
(Fig. S1B). PfCSP residues 83-91 formed an α-helix when bound by 5D5 Fab (Fig. 1B), in line 129 
with secondary structure predictions based on the primary sequence (Drozdetskiy et al., 2015). 130 
Importantly, while structures of a variety of polypeptides derived from PfCSP (the junctional 131 
region following N-CSP, the NANP repeat region, and the C-terminal αTSR domain) have been 132 
solved in complex with a broad range of antibodies (Oyen et al., 2017; Imkeller et al., 2018; Scally 133 
et al., 2018; Tan et al., 2018; Kisalu et al., 2018; Julien and Wardemann, 2019; Murugan et al., 134 
2019), our crystal structure of the 5D5 Fab in complex with PfCSP81-98 provides the first insight 135 
into the subdomain architecture of Pf N-CSP. However, further studies are needed to elucidate the 136 
conformation of residues comprising RI, which were disordered and unresolved in our crystal 137 
structure, as well as the overall structure of Pf N-CSP. 138 
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Figure 1. Molecular delineation of the mAb 5D5 epitope in PfCSP. (A, above) Schematic depicting the protein 141 
domain organization of PfCSP shown with the approximate location of Region I (RI) indicated by the black box and 142 
the junctional epitope represented by a dark red band. An approximate representation of PfCSP81-98 is illustrated by 143 
the black bar (not shown to scale). (Below) Heatmap of mAb 5D5 binding affinity for N-CSP single point mutant 144 
library. N-CSP residues included in PfCSP81-98 are indicated by the bracket at the bottom. The relative binding affinity 145 
is indicated by a diverging colour scale from red to blue, where red indicates a similar affinity while blue indicates 146 
decreased affinity. The X-axis denotes the N-CSP residue position and the Y-axis specifies the introduced single point 147 
mutations. Residues corresponding to the WT sequence are indicated by the gray dots. (B) Crystal structure showing 148 
the 5D5 Fab variable regions (heavy chain shown in red and kappa light chain shown in blue) bound to PfCSP N-149 
terminal residues 81-92 (yellow), which are recognized in an α-helical conformation. The N-linked glycan on H.Asn98 150 
of 5D5 Fab is represented as sticks. (C) mAb 5D5 CDRs contacting PfCSP. HCDRs 1, 2, and 3 (salmon, raspberry 151 
and firebrick red, respectively), and KCDRs 1 and 3 (light teal and deep teal, respectively) contribute to 5D5 Fab 152 
recognition, whereas KCDR2 (teal) does not. (D) Electrostatic surface potential of mAb 5D5 bound to PfCSP81-98. 153 
mAb 5D5 displays extensive shape and charge complementarity to PfCSP. Electrostatic calculations were performed 154 
using APBS (Baker et al., 2001) and rendered in Pymol (The PyMOL Molecular Graphics System, Version 2.0 155 
Schrödinger, LLC); scale: -5 kT/e (red) to +5 kT/e (blue). (E) H-bonds (shown as black dashed lines) formed between 156 
mAb 5D5 HCDR residues and negatively charged PfCSP residues. Water molecules are shown as red spheres.  157 
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mAb 5D5 contacts PfCSP with all complementarity-determining regions (CDRs) except 158 
kappa light chain CDR 2 (KCDR2; Fig. 1C). The heavy chain CDRs (HCDRs) form the majority 159 
of interactions with 498 Å2 buried surface area (BSA) compared to 160 Å2 BSA for the kappa light 160 
chain. Furthermore, the mAb 5D5 CDRs possess extensive shape and electrostatic 161 
complementarity to this highly charged N-CSP epitope (Fig. 1D). An electropositive pocket 162 
formed by HCDR2 contacts PfCSP residues D82 and E84 via H-bonds with Ser54Oγ, Asn56Nδ2, 163 
and Tyr58OH, and water-mediated H-bonds with Arg53N and Ser54Oγ (Fig. 1E). Additionally, an 164 
electronegative pocket formed by HCDR2, HCDR3, KCDR1, and KCDR3 contacts PfCSP 165 
electropositive residues R87, K90 and H91 via several H-bonds and salt bridges (Fig. 2A). The 166 
significance of this shape and charge complementarity for high affinity binding was observed in 167 
our yeast display experiments, as mutations maintaining both side chain length and electrostatic 168 
properties, such as K90R, were more likely to sustain high affinity binding than those that did not 169 
(K90E, K90D; Fig. 1A). 170 
Consistent with prediction from the primary mAb 5D5 sequence, we observed electron 171 
density for two GlcNAc and one α1-6Fuc moieties indicative of N-linked glycosylation at Asn98 172 
of HCDR3 (Fig. 2A and S1C). Importantly, the first N-linked GlcNAc moiety contacts the 173 
aliphatic portion of K90 of PfCSP81-98, conferring 48 Å2 of BSA, while the other sugars did not 174 
interact with the peptide. In this way, the paratope glycan contributes to mAb 5D5 occlusion of 175 
PfCSP residue K90. Interestingly, K90 is one of four lysine residues (including K85, K88, and 176 
K92) directly upstream of RI that have previously been proposed to be important for binding 177 
heparan sulfate proteoglycans on the surface of hepatocytes to initialize liver invasion (Zhao et al., 178 
2016). Notably, the α-helical conformation adopted by N-CSP residues 83-91 upon mAb 5D5 179 
binding positions the remaining three lysine residues, K85, K88 and K92, on the same exposed 180 
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face of the helix (Fig. S1B). Thus, our molecular description of PfCSP recognition by mAb 5D5 181 
demonstrates optimal antibody-antigen characteristics associated with high affinity binding to a 182 
putative functional site on Pf sporozoites. 183 
 184 
mAb 5D5 paratope glycosylation is critical for high affinity recognition of recombinant 185 
PfCSP 186 
To determine whether the N-linked glycan on H.Asn98 affects mAb 5D5 binding, we 187 
generated four different forms of the mAb 5D5 glycan and measured their binding kinetics to full-188 
length PfCSP using biolayer interferometry (BLI; Fig. 2B-F). Specifically, we generated four 5D5 189 
Fab variants with either: 1) a complex glycan, as in the crystal structure (by expression in HEK 190 
293F cells; 293F); 2) a high mannose glycan (by expression in HEK 293S (GnT I-/-) cells; 293S 191 
(GnT I-/-)); 3) a single GlcNAc moiety (by expression in HEK 293S (GnT I-/-) cells followed by 192 
Endo H treatment; Endo H); or 4) an H.N98Q mutation removing the N-linked glycosylation site 193 
altogether (5D5Dg). The 293F, 293S (GnT I-/-) and Endo H-treated 5D5 Fabs bound with high 194 
affinity to full-length PfCSP with KD’s of 39.7 ± 8.2 nM, 46.6 ± 4.7 nM and 85.8 ± 8.8 nM, 195 
respectively (Fig. 2C-E). In contrast, the 5D5Dg mutant Fab bound PfCSP with weaker affinity 196 
(KD of 453 ± 110 nM) due to an 11-fold faster off-rate compared to HEK 293F-expressed 5D5 Fab 197 
(Fig. 2B and F), while the on-rates of all glycoform Fabs remained within the same order of 198 
magnitude. Together with the crystal structure, these results underline the importance of the 199 
H.Asn98-linked GlcNAc moiety for high affinity mAb 5D5 binding to recombinant PfCSP, and 200 
highlight a rare occurrence for such a post-translational modification to participate in the antibody-201 
antigen interaction and improve the kinetics of antigen binding. 202 
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 203 
Figure 2. 5D5 paratope glycosylation mediates high affinity binding. (A) Interactions formed by mAb 5D5 204 
H.Asn98-linked GlcNAc moiety and surrounding CDR residues with PfCSP. H-bonds are shown as black dashed 205 
lines, and salt bridges are shown as blue dashed lines. (B-F) Binding kinetics of twofold dilutions of (C) 293F, (D) 206 
293S (GnT I-/-), (E) Endo H and (F) 5D5Dg Fab glycoform variants to full length PfCSP. (B) Mean kon and koff rates 207 
of the 5D5 Fab glycoform variants binding to full length PfCSP are plotted on the left and right y-axis, respectively. 208 
Mean kon rates are shown as red circles, and mean koff rates as blue triangles. (C-F) Representative sensorgrams are 209 
shown in black and 1:1 model best fits in red. Mean KD values are as listed. KD values, and kon and koff rates were 210 
determined by FortéBio’s Data Analysis software 9.0. Standard error values are reported as the standard deviation. 211 
Data are representative of three independent measurements. Corresponding glycan structures are shown using symbols 212 
adhering to the Symbol Nomenclature for Glycans (Varki et al., 2015) . 213 
 214 
mAb 5D5 does not efficiently bind or inhibit salivary gland Pf sporozoites 215 
The role of the N-linked glycan on H.Asn98 in the binding of 5D5 IgG to freshly isolated 216 
salivary gland Pf sporozoites was quantified by imaging flow cytometry. As these preparations 217 
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contained both live and dead sporozoites, we focused our analyses on live sporozoites that were 218 
negative for propidium iodide staining (Fig. S2). As positive and negative controls, we used human 219 
mAbs targeting the PfCSP central repeat (1210; Imkeller et al., 2018) and C-CSP (1710; Scally et 220 
al., 2018), respectively. In line with previous reports, mAb 1710 failed to recognize mature Pf 221 
sporozoites isolated from mosquito salivary glands, whereas mAb 1210 strongly bound these 222 
sporozoites (Fig. 3A-D). We detected a two-fold decrease in mean fluorescence intensity (MFI) 223 
between mAbs 1210- and 5D5- or 5D5Dg-bound sporozoites (Fig. 3C). The observed differences 224 
can be explained by the frequencies of the targeted epitopes on the sporozoite surface. Indeed, 225 
mAb 1210 likely binds repeated NANP motifs within the central region whereas mAbs 5D5 and 226 
5D5Dg can only react with a single N-CSP motif. In contrast to previous reports, we found that 227 
mAbs 5D5 did not bind the majority of sporozoites (Fig. 3B and D). Mutation of the glycosylation 228 
site further decreased the proportion of 5D5Dg-bound sporozoites from 27 to 13% (Fig. 3D). These 229 
results demonstrate the importance of mAb 5D5 paratope glycosylation for PfCSP binding on the 230 
sporozoite surface. However, they also reveal low levels of overall reactivity of this antibody to 231 
live salivary gland Pf sporozoites. 232 
 233 
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Figure 3. mAb 5D5 binding to salivary gland sporozoites and traversal inhibition activity. (A-D) Imaging flow 234 
cytometry of live salivary gland sporozoites isolated from mosquito thorax after incubation with human mAb 1710 or 235 
1210 (negative and positive controls, respectively), or mAb 5D5 or 5D5Dg. (A) Representative images of sporozoites 236 
in brightfield (BF, left panels) and mAb-bound fluorescent sporozoites (right panels). Scale bars - 5 µm. Total number 237 
of sporozoites analysed per condition is indicated in parentheses (N=3). (B) Comparative density plots of a 238 
representative experiment showing the fluorescence intensities of three arbitrarily-designated groups of mAb-bound 239 
sporozoites (neg – negative, + – low intensity, ++ – high intensity). (C) Mean fluorescence intensities (MFI) of the 240 
mAb-positive sporozoites. (D) Quantification of mAb-positive sporozoites (%). (C-D) Colors show results of three 241 
independent experiments. (E) Results of mAb inhibition of sporozoites in in vitro traversal assay tested at 100 µg/mL 242 
mAb concentration (N=3). Statistically significant differences (p<0.05) between the groups are indicated by different 243 
letters (z-test (C and D); paired Friedman test followed by Dunn’s post-hoc test (E)). 244 
 245 
We next evaluated how the low sporozoite binding observed for mAb 5D5 translated into 246 
inhibitory potency against Pf sporozoites in a hepatocyte traversal assay. In line with the mAb 247 
binding efficiencies, only mAb 1210 completely blocked sporozoite traversal of hepatocytes, 248 
whereas mAb 5D5 was as inefficient at inhibiting traversal as negative control mAb 1710, 249 
regardless of the presence of the paratope glycan (Fig. 3E). Poor mAb 5D5 binding to sporozoites 250 
and lack of traversal inhibition precluded further functional testing of mAb 5D5 in Pf infections in 251 
a sophisticated humanized mouse model. We conclude that, in spite of high affinity interaction 252 
with the N-CSP epitope in recombinant PfCSP, the overall low levels of mAb 5D5 binding to live 253 
Pf sporozoites preclude efficient inhibition of parasite traversal.  254 
 255 
mAb 5D5 does not inhibit in vivo sporozoite development in mosquitoes 256 
As CSP is essential for sporozoite development in mosquitoes (Menard et al., 1997), we 257 
extended our antibody binding and functional examination to immature Pf sporozoites isolated 258 
from oocysts in the mosquito midgut (Fig. 4A). Similar to our observations with mature 259 
sporozoites, mAb 5D5 exhibited low binding efficiency to immature sporozoites, as measured by 260 
MFI and percentage of mAb-positive sporozoites determined using imaging flow cytometry (Fig. 261 
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4B-C). Also consistent with our findings with salivary gland sporozoites, paratope glycosylation 262 
increased the proportion of mAb 5D5-bound midgut sporozoites by two-fold (Fig. 4D). 263 
 264 
Figure 4. mAb 5D5 binding to midgut sporozoites and inhibition of sporogonic development within mosquitoes. 265 
(A-D) Imaging flow cytometry of live midgut sporozoites isolated from oocysts after incubation with human mAb 266 
1710 or 1210 (negative and positive controls, respectively), or mAb 5D5 or 5D5Dg. (A) Representative images of 267 
sporozoites in brightfield (BF, left panels) and mAb-bound fluorescent sporozoites (right panels). Scale bars - 5 µm. 268 
Total number of sporozoites analysed per condition is indicated in parentheses (N=3). (B) Comparative density plots 269 
of a representative experiment showing the fluorescence intensities of three arbitrarily-designated groups of mAb-270 
bound sporozoites (neg – negative, + – low intensity, ++ – high intensity). (C) Mean fluorescence intensities (MFI) of 271 
the mAb-positive sporozoites. (D) Quantification of mAb-positive sporozoites (%). (C-D) Colors show results of three 272 
independent experiments. (E) Schematic representation of passive single-chain Fab (scFab) transfer by mosquito 273 
injection. (F) Results of scFab transfer experiments expressed relative to control PBS-injected mosquitoes (N=6, total 274 
mosquito numbers analyzed are indicated below in parentheses). The box plots show the upper and lower quantiles 275 
and the median of the distribution. Each dot represents normalized sporozoite loads in one experiment. Statistically 276 
significant differences (p<0.05) between the groups are indicated by different letters (z-test (C and D); maximum 277 
likelihood estimation (MLE)(F)).  278 
 279 
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To evaluate the inhibitory activity of mAb 5D5 against Pf sporozoites in their natural 280 
environment in vivo, we developed a passive mAb transfer assay for mosquitoes that examined 281 
sporozoite maturation and salivary gland invasion. Mosquitoes were injected with recombinant 282 
single-chain Fabs (scFabs) two days before Pf infection, and sporozoite loads in dissected salivary 283 
glands were quantified two weeks later (Fig. 4E). Injection of scFab1210 significantly reduced the 284 
number of mature sporozoites in the salivary glands. In contrast, transfer of scFab1710 or 285 
scFab5D5 did not affect sporozoite development and invasion (Fig. 4F). Taken together, these 286 
results demonstrate that mAb 5D5 fails to efficiently recognize its epitope on the surface of Pf 287 
parasites, and lacks inhibitory potency against sporozoites in both the vector and the host. 288 
 289 
Concluding Remarks 290 
 In this report, we demonstrate that despite high-affinity binding to recombinant PfCSP, 291 
mAb 5D5 does not recognize the majority of live Pf sporozoites, indicating that its epitope is not 292 
readily accessible or present on the sporozoite surface. Consequently, as shown in the current 293 
study, mAb 5D5 is unable to block Pf sporozoite development in the mosquito or inhibit sporozoite 294 
traversal of hepatocytes. The lack of potent human N-CSP-specific mAbs in multiple screens based 295 
on full-length recombinant PfCSP baits or unbiased antigen-agnostic approaches (Fig. S3; Triller 296 
et al., 2017; Murugan et al., 2018; Tan et al., 2018; Kisalu et al., 2018; Julien and Wardemann, 297 
2019) is in line with these observations. Overall, to date, there is little evidence to support N-CSP 298 
as a source of potent or protective epitopes to block Pf infection. Therefore, the repeating motifs 299 
in the central domain and N-terminal junction remain the most promising PfCSP regions for anti-300 
infective vaccine design to elicit protective mAbs.  301 
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Materials and Methods 302 
Mutant N-CSP yeast display library construction and transformation 303 
Epitope mapping using phage display was adapted from a previously published method 304 
(Van Blarcom et al., 2015). Construction of the mutant library required generation of a linearized 305 
vector and a library of mutant N-CSP inserts. The mutant insert library was generated by two 306 
rounds of PCR using primers that carried the randomized codon “NNK” (Tables S2 and S3), and 307 
mixing the products (Amplicons 1 to 9) at an equal molar ratio. The vector was generated by 308 
overlapping PCR using vector-F/R primers (Table S2). All PCR products were amplified using 309 
KOD DNA polymerase (EMD Millipore) and purified by gel extraction (Clontech Libraries).  310 
The EBY100 yeast strain was purchased from ATCC. The yeast vector was generated by 311 
modification of the commercially available pCTcon2 vector (Addgene; Chao et al., 2006). The 312 
mutant N-CSP insert was cloned with N-terminal V5 and C-terminal HA epitope tags. The Aga2p 313 
yeast protein gene was inserted downstream of the HA epitope tag to allow for yeast surface 314 
display of the N-CSP (plasmid pCTcon2-rsCSP-V5-HA-Aga2p). Yeast transformation was 315 
performed as described previously (Benatuil et al., 2010). In summary, 4 µg of the linearized yeast 316 
expression vector and 8 µg of the N-CSP mutant library insert were used for transformation. 317 
Transformants were plated on SDCAA plates and incubated at 30°C for 2 days. Over 108 colonies 318 
were collected, resuspended in YPD media with 15% glycerol, and stored at -80°C until use. 319 
5D5 Fab production and purification 320 
mAb 5D5 VL and VH regions were individually cloned into pcDNA3.4-TOPO expression 321 
vectors immediately upstream of human Igκ and Igγ1-CH1 domains, respectively. The resulting 322 
5D5 Fab light and heavy chain vectors were co-transfected into either HEK293F or HEK293S 323 
(GnT I-/-) cells for transient expression, and purified via KappaSelect affinity chromatography (GE 324 
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.13.904425doi: bioRxiv preprint 
 17 
Healthcare), cation exchange chromatography (MonoS, GE Healthcare), and size exclusion 325 
chromatography (Superdex 200 Increase 10/300 GL, GE Healthcare). For binding studies, 5D5 326 
Fab expressed in HEK293S (GnT I-/-) cells was digested with Endoglycosidase H, followed by an 327 
additional size exclusion chromatography step (Superdex 200 Increase 10/300 GL, GE 328 
Healthcare). Lastly, the 5D5Dg Fab was produced by site-directed mutagenesis of the mAb 5D5 329 
VH region using Accuprime Pfx Supermix (Thermo Fisher Scientific). 5D5Dg Fab was expressed 330 
in HEK293F cells and purified by chromatography as described above. 331 
IgG production and purification 332 
For yeast display experiments, mAb 5D5 was produced in ExpiCHO cells as a mouse IgG1 333 
with AVI tag for biotinylation. The IgG was then purified using protein G affinity chromatography 334 
(HiTrap Protein G HP, GE Healthcare) and size-exclusion chromatography (Superdex 200, GE 335 
Healthcare). Biotinylation was performed as previously described (Ekiert et al., 2011). 336 
For production of 5D5 and 5D5Dg IgGs for non-yeast display experiments, site-directed 337 
mutagenesis was performed using In-Fusion (Takara Bio) on the pcDNA3.4-TOPO vectors 338 
encoding the 5D5 Fab heavy chain and 5D5Dg Fab heavy chain sequences to substitute two stop 339 
codons with two residues (DK), allowing for expression of the Igγ1-CH2 and Igγ1-CH3 domains. 340 
5D5 IgG, 5D5Dg IgG, 1710 IgG (Scally et al., 2018), 1210 IgG (Imkeller et al., 2018), and IgGs 341 
elicited by the PfSPZ-CVac Challenge (Mordmüller et al., 2017; Murugan et al., 2018) were 342 
transiently expressed in HEK293F cells by co-transfection of paired Ig heavy and light chains, and 343 
purified through protein A affinity chromatography (GE Healthcare), followed by size exclusion 344 
chromatography (Superdex 200 Increase 10/300 GL, GE Healthcare). 345 
scFab production and purification 346 
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 scFab constructs were designed by cloning paired light and heavy chains, separated by a 347 
72-residue linker, into a pcDNA3.4-TOPO expression vector. The resulting constructs were 348 
transiently expressed in HEK293F cells, and purified by KappaSelect affinity chromatography 349 
(GE Healthcare), followed by size exclusion chromatography (Superdex 200 Increase 10/300 GL, 350 
GE Healthcare). 351 
Recombinant PfCSP production and purification 352 
A construct of full-length PfCSP isolated from strain NF54 (UniProt accession no. P19597, 353 
residues 20-384) was designed with potential N-linked glycosylation sites mutated to glutamine 354 
(Scally et al., 2018). The resulting construct was transiently transfected in HEK293F cells, and 355 
purified by HisTrap FF affinity chromatography (GE Healthcare) and size exclusion 356 
chromatography (Superdex 200 Increase 10/300 GL, GE Healthcare). 357 
A construct encoding PfCSP residues 71-104 was cloned into a pETM-22 vector. 358 
Competent BL21(DE3) E. coli cells were transformed with the resulting plasmid and cultured to 359 
an optical density of approximately 0.6-0.8. Expression of PfCSP71-104 was induced using 1 mM 360 
isopropyl β-D-1-thiogalactopyranoside (IPTG). Approximately 4 h after induction, cells were 361 
lysed by sonication, and purified through HisTrap affinity chromatography (GE Healthcare) and 362 
size exclusion chromatography (Superdex 75 10/300 GL, GE Healthcare). 363 
Yeast display epitope mapping 364 
For each sorting round, ~109 yeast cells from the frozen stock were cultured in 250 mL of 365 
SDCAA media for 16 h at 27.5°C until an OD of 1.9 was reached. Cells were pelleted, resuspended 366 
in 35 mL of SGR-CAA induction media and incubated for 30 h at 18°C until an OD of 1.4 was 367 
reached. After harvesting approximately 8 mL of cell culture, the pellet was washed 3 times with 368 
PBS and finally resuspended in 5 mL of PBS. Biotinylated 5D5 IgG was incubated with BB515-369 
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streptavidin at a molar ratio of 1:2 for 20 min. The biotinylated 5D5 IgG-streptavidin BB515 370 
complex and Anti-HA PE antibody were added to the 5 mL of resuspended yeast cells with a final 371 
concentration of 20 nM for each stain, followed by overnight incubation at 4°C with head-to-head 372 
rotation in the dark. Next, cells were washed twice with PBS, resuspended in 5 mL of PBS, and 373 
sorted at the TSRI Flow Cytometry Core Facility. Two gates were applied for simultaneous sorting 374 
(Fig. S1A): one where binding of 5D5 IgG was completely abrogated (PE only) and one where 375 
binding was unaffected (PE and BB515). The second round of sorting saw significant enrichment 376 
in either gate.  377 
Deep mutational scanning data analysis 378 
Sequencing data were obtained in FASTQ format and parsed using SeqIO module in 379 
BioPython (Cock et al., 2009). After trimming the primers, a paired-end read was then filtered and 380 
removed if the corresponding forward and reverse reads were not reverse-complemented. The 381 
position of the randomized codon was then identified by the internal barcode. Each mutation was 382 
called by comparing individual paired-end reads to the wild type (WT) reference sequence. 383 
Frequency of mutation m in sample s was computed as: 384 
𝐹𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦),+ 	= 𝑟𝑒𝑎𝑑	𝑐𝑜𝑢𝑛𝑡),+ + 1𝑡𝑜𝑡𝑎𝑙	𝑟𝑒𝑎𝑑	𝑐𝑜𝑢𝑛𝑡+  385 
Relative affinity of mutation m was computed as: 386 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒	𝑎𝑓𝑓𝑖𝑛𝑖𝑡𝑦) = log<= >𝐹𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦),?@ABC	D	EFGH	<𝐹𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦),?@ABC	D	EFGH	D ÷ 𝐹𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦JK,?@ABC	D	EFGH	<𝐹𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦JK,?@ABC	D	EFGH	DL 387 
The pseudo read count of 1 in the calculation of frequency was to prevent division by zero during 388 
the calculation of relative affinity. Relative affinity of WT is 0.  389 
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Raw sequencing data have been submitted to the NIH Short Read Archive under accession 390 
number: BioProject PRJNA578947. Custom python scripts for analyzing the deep mutational 391 
scanning data have been deposited to https://github.com/wchnicholas/CSP_Nterm_yeast_display. 392 
Crystallization and structure determination 393 
Purified 5D5 Fab and CSP 81-98 peptide (GenScript) were mixed in a 1:5 molar ratio. The 394 
5D5 Fab/CSP 81-98 complex was then mixed in a 1:1 ratio with 20% (w/v) PEG 3350, 0.2 M di-395 
ammonium citrate. Crystals appeared after ~20 h, and were cryoprotected in 15% (v/v) ethylene 396 
glycol before being flash-frozen in liquid nitrogen. Data were collected at the 08ID-1 beamline at 397 
the Canadian Light Source, processed and scaled using XDS (Kabsch, 2010). The structure was 398 
determined by molecular replacement using Phaser (McCoy et al., 2007) and a Fab model from 399 
our internal database as the search model. Refinement of the structure was performed using 400 
phenix.refine (Adams et al., 2010) and iterations of refinement using Coot (Emsley et al., 2010). 401 
The crystal structure has been deposited in the Protein Data Bank (PDB ID 6UUD). 402 
BLI binding studies 403 
BLI (Octet RED96, FortéBio) experiments were conducted to determine the binding 404 
kinetics of the 5D5 Fab glycoform variants to recombinant PfCSP diluted to 10 µg/mL in kinetics 405 
buffer (PBS, pH 7.4, 0.01% [w/v] BSA, 0.002% [v/v] Tween-20) was immobilized onto Ni-NTA 406 
(NTA) biosensors (FortéBio). After a steady baseline was established, biosensors were dipped into 407 
wells containing twofold dilutions of each 5D5 Fab glycoform variant in kinetics buffer. Tips were 408 
then immersed back into kinetics buffer for measurement of the dissociation rate. Kinetics data 409 
were analyzed using FortéBio’s Data Analysis software 9.0, and curves were fitted to a 1:1 binding 410 
model. Mean kinetic constants and corresponding standard deviation values are reported as the 411 
result of three independent experiments for each 5D5 Fab glycoform variant. 412 
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BLI experiments were also done to determine the avidity of IgGs isolated from the PfSPZ-413 
CVac Challenge (Mordmüller et al., 2017) to full length recombinant PfCSP and N-CSP construct, 414 
PfCSP71-104. Unrelated malaria protein Pfs25 was used to block non-specific binding and 5D5 IgG 415 
was used as a positive control. PfCSP71-104, PfCSP or Pfs25 was diluted to 10 µg/mL in kinetics 416 
buffer and immobilized onto Ni-NTA (NTA) biosensors (FortéBio). Once a stable baseline was 417 
established, biosensors were dipped into wells, each containing a different IgG diluted to 500 nM 418 
in kinetics buffer. Tips were subsequently dipped back into kinetics buffer to observe any 419 
dissociation of IgG. 420 
Mosquito rearing, parasite infections and sporozoite isolations 421 
Anopheles coluzzii (Ngousso strain) mosquitoes were maintained at 29°C 70–80% 422 
humidity 12/12 h day/night cycle. For P. falciparum infections, mosquitoes were fed for 15 min 423 
on a membrane feeder with NF54 gametocytes cultured with O+ human red blood cells (Haema, 424 
Berlin), and, thereafter, kept in a secured S3 laboratory according to the national regulations 425 
(Landesamt für Gesundheit und Soziales, project number 297/13). The P. falciparum NF54 clone 426 
used in this study originated from Prof. Sauerwein’s laboratory (RUMC, Nijmegen) and was 427 
authenticated for Pfs47 genotype by PCR on genomic DNA. P. falciparum asexual cultures were 428 
monthly tested for Mycoplasma contamination. Unfed mosquitoes were removed shortly after 429 
infections. Blood fed mosquitoes were offered an additional uninfected blood meal eight days post 430 
infection, maintained at 26°C for 12 and 14/15 days, and used for the midgut and salivary gland 431 
dissections, respectively. The midgut or salivary gland sporozoites were isolated into HC-04 432 
complete culture medium (MEM without L-glutamine (Gibco) supplemented with F-12 Nutrient 433 
Mix with L-glutamine (Gibco) in 1:1 ratio, 15 mM HEPES, 1.5 g/L NaHCO3, 2.5 mM additional 434 
L-glutamine, 10% FCS) and kept on ice until further use. 435 
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Imaging flow cytometry of sporozoites 436 
Isolated sporozoites were diluted in PBS/1% FCS to 3x106/mL and incubated for 30 min 437 
at 4°C with 1 µg/mL recombinant IgGs, washed (16,000 x g, 4 min, 4°C) and incubated with Cy5-438 
conjugated anti-human IgG1 (0.4 µg/ml, DRFZ Core Facility, Berlin) for 30 min at 4°C. After 439 
incubation with the secondary antibody, sporozoites were further incubated with propidium iodide 440 
(20 µg/mL, Sigma Aldrich) for 5 min at room temperature as previously described (Costa et al., 441 
2018). Sporozoites were acquired after one wash in PBS using the ImageStreamX Mk II instrument 442 
(Merck Millipore) with a 60X objective for 15-20 min per sample. The experiments were 443 
performed in three replicates. To avoid a possible bias due to the variable pre-acquisition waiting 444 
times on ice, the order of samples was swapped between the experimental replicates. 445 
Quantification of propidium iodide staining was performed using the Intensity_MC_Ch04, 446 
whereas mAb binding was quantified by Cy5-conjugated secondary antibody signal 447 
Intensity_MC_Ch11. Single sporozoites were manually selected by brightfield images (Channel 448 
9) and only live, propidium iodide-negative sporozoites were gated for mAbs binding efficiency 449 
analysis (for gating strategy see Fig. S2). The analysis was performed with IDEAS 6.2 (Merck 450 
Millipore). Raw data were exported as .txt files and represented in dot and density plots using 451 
RStudio Version 1.1.453. 452 
Pf sporozoite hepatocyte traversal assay 453 
Pf traversal assays were performed as previously described (Triller et al., 2017). In brief, 454 
the salivary gland sporozoites were isolated from mosquito thorax and treated with mAbs (100 455 
µg/mL) for 30 min on ice. The sporozoite preparations were seeded on human hepatocytes (HC-456 
04; Sattabongkot et al., 2006) for 2 h at 37°C and 5% CO2 in the presence of dextran-rhodamine 457 
(0.5 mg/mL) (Molecular Probes). mAb-untreated Pf sporozoites were used to measure the 458 
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maximum traversal capacity. Cells incubated only with uninfected mosquito thoracic material 459 
were used as a background control. Cells were washed and fixed with 1% (v/v) formaldehyde in 460 
PBS. Dextran positivity was detected by FACS LSR II instrument (BD Biosciences). Data analysis 461 
was performed by background subtraction and normalization to the maximum traversal capacity 462 
of mAb-untreated Pf sporozoites using FlowJo v.10.0.8 (Tree Star). 463 
Passive transfer of scFabs into mosquitoes 464 
1-2-day-old female A. coluzzii mosquitoes were injected on ice with 100 ng (285 µL) of scFab 465 
diluted in PBS or with 285 µL PBS as an injection control. Two days later, mosquitoes were 466 
infected with P. falciparum NF54 following the protocol described above. Mosquito heads were 467 
carefully pulled off 14 days later and the attached salivary glands were collected and washed with 468 
PBS. Dissected salivary glands were pooled for each group, homogenized and the freshly isolated 469 
sporozoites were counted using a Malassez hemocytometer. The average number of sporozoites 470 
per mosquito was calculated for each group. 471 
Enzyme-linked immunosorbent assay 472 
Antigen ELISA detHigh binding 384 well polystyrene plates (Corning) were coated with 473 
recombinantly expressed PfCSP71-104 comprising N-CSP at 50 ng/well overnight at 4°C. 1% BSA 474 
in PBS was used for blocking the wells at RT. Binding of mAbs to N-CSP was determined by 475 
incubating the coated plates with serially diluted mAb at 4.00, 1.00, 0.25, 0.06 µg/mL 476 
concentrations. Bound mAb was detected using goat anti–human IgG-HRP (Jackson 477 
ImmunoResearch) at 1:1,000 dilution in 1% BSA in PBS and One-step ABTS substrate (Roche). 478 
Non-PfCSP reactive antibody, mGO53, was used as negative control (Wardemann et al., 2003). 479 
Area under the curve (AUC) based on diluted antibody series was calculated using GraphPad 480 
Prism 7.04 (GraphPad).  481 
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Statistical analysis  482 
No samples were excluded from the analyses. Mosquitoes from the same batches were 483 
randomly allocated to the experimental groups (age range: 1–2 days). The experimenters were not 484 
blinded to the group allocation during the experiment and/or when assessing the outcome. Sample 485 
sizes were chosen according to best practices in the field and previous experience (Costa et al., 486 
2018). 487 
For Figures 3C and 4C, Mean Fluorescence Intensity (MFI) and standard error of the mean 488 
(SEM) of the mAb-bound live sporozoites were first computed from the data. We then associated 489 
an MFI and standard error to each treatment by computing the average MFI across the three 490 
independent experiments and subsequently computing the standard deviation (STD) as STD = 491 
[(SEM12+ SEM22+ SEM32)1/2]/3. The null hypothesis was that the MFIs of sporozoites bound by 492 
the tested mAbs were not different. Due to the large sample sizes examined, a z-test was used to 493 
compare the MFI of the three conditions, and the obtained p-values are summarized below with 494 
significant p-values highlighted in green: 495 
 496 
 497 
  498 
 499 
The combined p-values from the z-test were much smaller than the total sample size, which is 500 
roughly 104. p-values much smaller than the inverse of the population size were therefore rounded 501 
up to 10-4. 502 
For Figures 3D and 4D, sample sizes (tot1) and proportion of mAb-bound sporozoites per 503 
experiments (pos1) for each independent experiment (N=3) are summarized below:  504 
Fig. 4C 5D5 5D5Dg 
1210 <10-4 <10-4 
5D5 - 0.3 
5D5Dg  - 
 
Fig. 3C 5D5 5D5Dg 
1210 <10-4 <10-4 
 5D5 - 0.2 
5D5Dg  - 
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The null hypothesis was that the proportions of sporozoites bound by the tested mAbs were not 513 
different. Normality was verified and a z-test was used to compare the fractions of mAb-bound 514 
sporozoites. We first computed the fraction 𝑓 of mAb-bound for each mosquito tissue, experiment 515 
and treatment as 𝑓M = posM totM⁄ 	. The fraction 𝑓 can be considered as the probability that a 516 
sporozoite taken at random is bound by a certain mAb. The error associated to 𝑓 is therefore given 517 
by  𝑠(𝑓) = R𝑓(1 − 𝑓) 𝑁⁄  , where N is the sample size given in the column tot1. Within each 518 
experiment, we used a two-sided z-test to test the null hypothesis that the fractions 𝑓 associated to 519 
the tested mAbs were not different, resulting in six pairwise comparisons per experiment. The 520 
resulting p-values from the three independent experiments were combined using Fisher method 521 





For both Figures 3D and 4D, the fractions 𝑓 organized from strong to weak are as follows: 1210, 527 
5D5, 5D5Dg, 1710. The combined p-values computed with the Fisher method are much smaller 528 
than the total sample size, which is roughly 104. The reported p-values are therefore the inverse of 529 
the total sample size. 530 
Fig. 3D Exp 1 Exp 2 Exp 3 
 tot1 pos1 tot1 pos1 tot1 pos1 
1710 806 0 589 1 1121 1 
1210 266 223 447 401 138 112 
5D5 545 176 487 82 1096 316 
5D5Dg 592 95 665 69 653 81 
 
Fig. 4D Exp 1 Exp 2 Exp 3 
 tot1 pos1 tot1 pos1 tot1 pos1 
1710 901 2 1987 1 1267 4 
1210 222 219 681 675 837 831 
5D5 262 67 728 229 1456 366 
5D5Dg 471 72 738 97 1482 193 
 
Fig. 4D 1210 5D5 5D5Dg 
1710 <10-4 <10-4 <10-4 
1210 - <10-4 <10-4 
5D5  - <10-4 
 
Fig. 3D 1210 5D5 5D5Dg 
1710 <10-4 <10-4 <10-4 
1210 - <10-4 <10-4 
5D5  - <10-4 
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Statistical analysis in Figure 3E was performed using GraphPad Prism 8 (paired Friedman 531 
test followed by Dunn’s post-hoc test, paired values for mAb treatment per experiment) and p-532 
values below 0.05 were considered significant (*p < 0.05). 533 
For Figure 4F, number of dissected mosquitoes and mean number of sporozoites per 534 
mosquito in each independent experiment (N=6) are summarized below:  535 
 536 













The null hypothesis was that the average number of sporozoites for each scFab and for each 550 
experiment independently was not significantly different. To perform this test, we used the number 551 
of oocysts per mosquito from the same experiments (data available upon request). We have 552 
assumed that the number of oocysts per mosquito follows a negative binomial distribution with 553 




that gives the probability that the number	𝑋 of oocysts in one mosquito is equal to 𝑚, for 𝑚	 =558 	0, 1, 2, etc.	We determined the two parameters 𝑀 and 𝑘 using a Bayesian approach with the 559 
Metropolis-Hastings algorithm and determined their MLE (code available upon request). The 560 
estimates for 𝑘 are given here: 561 
 PBS 5D5 1710 1210 
Exp     
1 33 33 33 33 
2 20 23 13 20 
3 23 23 23 23 
4 20 20 20 20 
5 24 24 24 24 
6 21 21 21 21 
Numbers of dissected mosquitoes 
 PBS 5D5 1710 1210 
Exp     
1 34285 60612 46394 15510 
2 22545 15058 10505 8803 
3 7733 7304 13743 5333 
4 6625 5000 4250 3750 
5 811 1275 579 115 
6 30095 19428 31047 14666 
 
 
Mean number of sporozoites per mosquito 
Pr{𝑋 = 𝑚	|	𝑘, 	𝑀} = 	 𝛤(𝑚 + 𝑘)𝛤(𝑘)	𝑚! g 𝑘𝑀 + 𝑘hi g 𝑀𝑀+ 𝑘h)  
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We then assumed that the number of sporozoites was linearly proportional to the number of oocysts 569 
(Vaughan et al., 1992; Stone et al., 2013; Miura et al., 2019). This allowed us to replace 𝑀 (as 570 
derived from oocysts distribution) in the negative binomial with the average sporozoite number as 571 
given above. We used the MLE estimate of the shape parameter 𝑘 and simulated 10,000 572 
independent samples of mosquitoes of size given above. Each simulated sample is thus statistically 573 
identical to those provided by the experimental data.  574 
Finally, for each two treatments and for each pair of simulated samples, we tested the null 575 
hypothesis that there is no difference between the treatments by random sampling while keeping 576 
sample sizes as in the experimental data. We thus created a distribution of the difference between 577 
the average number of sporozoites in the two treatments to be compared under this null 578 
hypothesis. The comparison of this distribution with the difference in sporozoite numbers as 579 
given by the experimental data produces the 𝑝-value listed below. The combined p-value using 580 
the Fisher method and true from false positives were discriminated using the Benjamini-581 
Hochberg (BH) and the Benjamini-Liu (BL) methods at a false discovery rate 𝑄 = 10kl.   582 
 PBS 5D5 1710 1210 
Exp     
1 21 25 15 16 
2 27 18 27 28 
3 11 11 11 11 
4 17 22 20 19 
5 19 16 16 18 
6 16 20 20 17 
Numbers of dissected mosquitoes  
used for oocyst count to perform  
MLE estimates 
 PBS 5D5 1710 1210 
Exp     
1 1.15 1.07 1.37 0.97 
2 0.33 0.14 0.36 0.42 
3 33.3 2.44 1.76 1.37 
4 0.43 0.22 0.32 0.52 
5 0.47 0.38 0.56 0.36 
6 0.43 0.26 0.39 0.27 
Shape parameter k (MLE) 
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To check the consistency of this method, we simulated the sampled mosquito populations but 590 
skipped the shuffling across the samples.  591 
 592 
(Online) Supplemental Material 593 
Supplemental materials include three tables and three figures. Supplemental tables: X-ray 594 
crystallography data collection and refinement (Table S1), description of primers used to generate 595 
mutant insert library for yeast display (Table S2), and PCR reactions and products for mutant insert 596 
library construction (Table S3). Supplemental figures: Experimental details of fluorescence-597 
activated cell sorting of 5D5 IgG yeast display epitope mapping library and crystal structure 598 
(Figure S1), gating strategy for imaging flow cytometry quantification of mAb binding to live Pf 599 
sporozoites (Figure S2), and human mAbs against the PfCSP N-CSP identified from analysis of 600 
the PfSPZ-CVac samples (Figure S3). 601 
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  exp1 exp2 exp3 exp4 exp5 exp6 Fisher BH BL 
trmt1 trmt2        Q = 1e-3 
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PBS 1710 0.91 0.14 0.99 0.19 0.21 0.53 0.45 False False 
PBS 1210 2e-3 0.07 0.02 0.12 0.01 0.09 8e-6 True True 
5D5 1710 0.13 0.34 0.99 0.39 0.06 0.81 0.29 False False 
5D5 1210 1e-4 0.22 0.08 0.30 0.01 0.31 1e-4 True True 
1710 1210 3e-4 0.36 1e-3 0.40 0.01 0.09 3e-6 True True 
Comparison between treatments across experiments, p-values and FDR analysis. 
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